Expression of non-neuronal Tau in humans and mice

This study validates the expression of Tau protein in various non-neuronal human and mouse tissues, including the kidney, muscle, and pancreas, suggesting that its dysregulation may contribute to diseases beyond neurodegeneration.

The Gist

Imagine your body is a bustling city. For decades, scientists thought a specific protein called Tau was like a specialized construction crew that only worked in one very important district: the Brain. Their job was to build and maintain the "roads" (microtubules) that transport goods and messages inside brain cells. When this crew gets confused or breaks down, it causes traffic jams that lead to devastating diseases like Alzheimer's.

But this new study asks a simple question: "Is the Tau crew only working in the brain, or are they also showing up at the construction sites in the rest of the city?"

Here is the story of what they found, explained simply:

1. The Problem: The "Flashlight" Was Too Dim

The researchers knew that Tau might exist in other parts of the body (like the heart, kidneys, and pancreas), but it's there in very tiny amounts—like a faint whisper compared to the loud shout in the brain.

The problem was that the tools scientists used to find Tau (called antibodies) were like flashlights. Some flashlights were too dim to see the faint whispers in the non-brain tissues. Others were "fuzzy," lighting up things that weren't actually Tau.

To fix this, the team used a special "Traffic Light System" they developed previously. They picked three specific, high-quality flashlights (antibodies) that they knew were sharp and accurate. They also used a special chemical "eraser" (lambda phosphatase) to wipe away sticky tags (phosphorylation) that often hide Tau, making it easier to see the protein clearly.

2. The Investigation: A City-Wide Search

The team took a massive "map" of the human and mouse body, consisting of tiny samples from 33 mouse tissues and 66 human tissues. They shined their high-quality flashlights on these samples to see where Tau was hiding.

What they found:

• The Brain: As expected, the brain was packed with Tau. The construction crew was everywhere, building roads.
• The Rest of the Body: Surprise! They found Tau in many other places, but it was much quieter there.
  • Found: Salivary glands (where saliva is made), kidneys, skeletal muscles, the heart, the pancreas, and the esophagus (the food pipe).
  • Not Found (or very hard to find): The testicles, spleen, lungs, and bone marrow (at least with the tools they used).

3. The Twist: It's Not Just the Nerves

A major mystery was: Is Tau in the heart and pancreas because those organs are full of nerves (which naturally have Tau), or is it actually inside the heart and pancreas cells themselves?

The researchers zoomed in and found that Tau is actually inside the cells of these organs, not just the nerves running through them.

• The Pancreas: This is a big deal. The pancreas makes insulin (which controls blood sugar). They found Tau inside the "beta cells" that make insulin. This suggests Tau might be helping to organize the delivery of insulin, like a foreman organizing trucks. If Tau gets messed up here, it could contribute to Type 2 Diabetes.
• The Nucleus: In some cells (like in the kidney and pancreas), they even saw Tau hanging out in the cell's "control center" (the nucleus), not just on the roads. We don't fully know what it's doing there yet, but it's a new discovery.

4. The Takeaway: Why Should You Care?

This study changes the map.

• Old Map: Tau is only a brain protein.
• New Map: Tau is a "city-wide" protein. It works in the brain, but it also has jobs in the heart, kidneys, and pancreas.

The Big Picture:
If Tau is involved in diabetes, heart health, or kidney function, then when we study diseases like Alzheimer's, we might be missing the bigger picture. Conversely, if we understand how Tau works in the pancreas, we might find new ways to treat diabetes.

In a nutshell: The researchers cleaned their tools, looked everywhere, and discovered that the "brain protein" Tau is actually a hardworking citizen living in many neighborhoods of the body, not just the brain. This opens up a whole new world of research into how this protein affects our overall health.

Technical Summary

1. Problem Statement

Tau protein, encoded by the MAPT gene, is traditionally characterized as a neuronal protein essential for cytoskeletal stability and intracellular transport. Its dysregulation is a hallmark of neurodegenerative diseases (e.g., Alzheimer's, Parkinson's). While emerging evidence suggests Tau is expressed in non-neuronal peripheral tissues (muscle, kidney, pancreas, etc.), this remains poorly understood due to two main challenges:

• Low Expression Levels: Non-neuronal Tau expression is significantly lower than in the central nervous system (CNS), making detection difficult.
• Antibody Specificity: Many widely used "total" anti-Tau antibodies are sensitive to post-translational modifications (PTMs), particularly phosphorylation. This leads to inconsistent results and cross-reactivity, hindering the reliable characterization of Tau in peripheral tissues.

2. Methodology

The study employed a rigorous, multi-modal approach to validate Tau expression across species and tissues:

• Antibody Selection (The "Traffic Light System"): The authors utilized three previously validated antibodies based on a robust selection framework:
  • Tau-12: Recognizes the N-terminal region (Total Tau).
  • Tau-1: Recognizes dephosphorylated Tau at residues Ser195-Thr205 (Mid-domain).
  • RD3: Recognizes the 3R Tau isoform.
• Tissue Sources:
  • Human: 66 adult donors comprising 22 normal tissue types (FFPE TMAs from AMS Biotechnology).
  • Mouse: 18 normal tissue types from ICR mice (genetically diverse) and specific wild-type C57Bl/6J mouse pancreas sections.
• Experimental Procedures:
  • Pre-treatment: All Tissue Microarrays (TMAs) and Western Blot (WB) membranes were treated with Lambda Protein Phosphatase (λPP) to remove phosphate groups. This was critical to unmask epitopes and ensure consistent antibody binding regardless of the phosphorylation state.
  • Immunohistochemistry (IHC): Performed on TMAs using the selected antibodies. Slides were scanned at 40x magnification.
  • Western Blotting: Human tissue lysates were analyzed to confirm molecular weight (50–70 kDa) and relative abundance.
  • Image Analysis: Quantification of DAB immunolabelling was performed using the HALO® platform (Area Quantification module). Statistical significance was determined via One-way ANOVA with Tukey's post hoc test.

3. Key Contributions

• Systematic Validation: This study provides one of the most comprehensive validations of anti-Tau antibodies in non-neuronal tissues, addressing the critical issue of antibody specificity in low-expression environments.
• De-phosphorylation Strategy: The authors demonstrated that pre-treating tissues with λPP is essential for detecting low-level Tau in peripheral tissues, as phosphorylation often masks epitopes for "total" Tau antibodies.
• Cross-Species Comparison: The study directly compared Tau expression patterns between humans and mice using high-quality, FDA-grade tissue microarrays.

4. Key Results

A. Central Nervous System (CNS) Validation:

• All three antibodies (Tau-12, Tau-1, RD3) successfully detected Tau in human and mouse brain regions (cerebellum, cerebrum, pituitary) and peripheral nerves.
• Nuclear Localization: Tau was observed in the nucleus of a subset of cells in both CNS and peripheral tissues, supporting emerging theories of a nuclear role for Tau.
• Quantification: CNS Tau optical density (OD) ranged from 0.2–0.9, significantly higher than peripheral tissues (0.2–0.3).

B. Peripheral Tissue Expression:

• Confirmed Positive Tissues: Tau expression was definitively confirmed in the salivary gland, kidney, skeletal muscle, heart, pancreas, and oesophagus in both humans and mice.
  • In the pancreas, Tau was localized to islets (specifically β-cells), confirming previous reports.
  • In the mouse pancreas, initial TMA scans missed islets due to sampling; specific sectioning of mouse pancreas confirmed Tau presence.
• Negative/Restricted Tissues:
  • In tissues like the prostate, stomach, thymus, colon, ovary, and liver, Tau staining was restricted to nerves (innervation) rather than parenchymal cells.
  • No signal was detected in the testis, spleen, lung, and bone marrow, contradicting some previous literature that suggested expression in these areas.
• Isoform Specificity: The RD3 antibody (3R isoform) showed significant variation in signal intensity across tissues (strongest in kidney and pancreas, weakest in salivary gland and muscle), suggesting isoform-specific distribution.

C. Western Blot Findings:

• Strong 50–70 kDa bands were detected in the brain.
• Weaker bands in the 50–70 kDa range were detected in the pancreas and heart, with even weaker signals in kidney, muscle, and liver.
• Low molecular weight variants (26–40 kDa) were observed in the heart, skeletal muscle, and liver.

5. Significance and Implications

• Beyond Neurodegeneration: The findings confirm that Tau is a ubiquitous protein with cell-type-specific expression in peripheral organs, not just a neuronal marker.
• Metabolic Disease Link: The confirmed presence of Tau in pancreatic islets supports the hypothesis that Tau dysregulation may play a role in Type 2 Diabetes (T2D) and insulin secretion, potentially linking metabolic disorders with Tau pathology.
• Methodological Standard: The study establishes that without phosphatase treatment and highly specific antibodies, non-neuronal Tau is likely under-detected or mischaracterized.
• Future Directions: The authors suggest that Tau could be a novel therapeutic target for metabolic diseases and that future research must focus on understanding the specific functions of Tau isoforms in non-neuronal cells and how their dysregulation contributes to non-neurodegenerative pathologies.

Limitations Noted:

• TMAs represent only a fraction of tissue structures, potentially missing rare Tau-positive cells.
• Pre-treatment with λPP removes information about the native phosphorylation state of Tau in these tissues.
• The study used normal adult tissues, so age- or disease-related variations were not captured.